Aurum Ventures MKI
Aurum Ventures MKI provides value added growth capital to exceptional entrepreneurs within the fields of life-sciences and clean-tech. While we focus on investing in unique, cutting edge technologies that will mature into successful business companies, our investments reflect our own values, so we prefer investing in companies that, through their sound commercial propositions, also contribute to the well-being of mankind. Our team is comprised of senior and experienced hands-on executives who work actively with the portfolio companies in enhancing their strategic and execution capabilities. We typically take a long-term approach, understanding that ventures in the life sciences and clean tech take time to mature and be successful.
Scopio Labs Ltd. is a Tel Aviv-based company that specializes in the development of digital microscopes utilizing computational imaging technology. Founded in 2015, the company focuses on creating innovative diagnostics solutions for various applications, including cancer screening, hematology, cytology, academic research, and drug discovery. Its advanced platform aims to enhance diagnostic accuracy and streamline research processes in the life sciences sector.
KidneyCure Ltd. is developing proprietary cell therapies aiming to prevent progression of Chronic Kidney Disease. The scientific basis and motivation for KidneyCure’s approach was provided by a world-renowned authority in Nephrology Prof. Benjamin Dekel, through genuinely pioneering research carried in his laboratory at Sheba Medical Center in Israel, one of the world’s leading medical centers. KidneyCure’s unique 3D renal cell cluster technology is expected to significantly delay the need for dialysis and transplantation and give millions of patients an opportunity to live longer higher quality lives.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
LifeBond Ltd. specializes in the development and manufacturing of absorbable bio-surgical medical devices aimed at enhancing tissue repair and improving patient recovery. Founded in 2006 and based in Caesarea, Israel, the company offers innovative products such as LifeSeal, a surgical sealant designed to reinforce staple lines in bariatric and colorectal surgeries, thereby minimizing complications like leakage. Another key product is LifeMesh, a self-fixating mesh intended for hernia repair, which is currently in pre-clinical development. LifeBond’s portfolio also includes tissue adhesives and absorbable hemostats. The company's devices are designed to meet various surgical needs, leveraging their natural origin, elasticity, adhesiveness, and durability. LifeBond's products are available in multiple regions, including China, the United States, and Europe, although they are still under investigation and have not received market approval.
CorAssist Cardiovascular Ltd. is a clinical stage medical device company based in Haifa, Israel, focused on developing innovative solutions for heart failure with preserved ejection fraction and diastolic dysfunction. The company's primary products include CORolla, an elastic self-expanding device designed to be implanted within the left ventricle using minimally invasive techniques. This device enhances diastolic function by improving filling performance without the need for an external power source. Another product, ImCardia, also an elastic self-expanding device, is designed to be attached to the external surface of the left ventricle through a straightforward off-pump procedure. Founded in 2003, CorAssist aims to advance therapeutic options for patients suffering from heart-related conditions.
BPT is developing and commercializing advanced membranes-based separation solutions addressing the unique needs of the water and wastewater treatment for key industrial processes. BPT patented chemically-stable membrane technology enable customers in the landfill, mining, chemical, biopharma and food industries to comply with the environmental regulations, reuse water and reduce production costs. BPT membranes are field proven to enable lowest cost reclamation of some of the most aggressive and vexing industrial waste water streams.